Kaiser Permanente to Commence Use of Second Cxbladder Test

KAISER PERMANENTE TO COMMENCE COMMERCIAL USE OF SECOND CXBLADDER TEST Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to announce that it has been informed by Kaiser Permanente that it intends to commence the commercial use of a second Cxbladder product, Cxbladder Triage, from the beginning of July 2021. In June 2020, Kaiser Permanente approved the commercial use of Cxbladder products by its urologists for patients being evaluated and managed for bladder cancer. Kaiser Permanente commenced its commercial use with Cxbladder Monitor for patients being monitored for the recurrence of bladder and urothelial cancer. Kaiser Permanente has now informed Pacific Edge that it intends to commence the commercial use of a second Cxbladder product, Cxbladder Triage for patients presenting with haematuria (blood in the urine and a key indicator of bladder cancer). Kaiser Permanente will start its commercial use of Cxbladder Triage in a single clinic comprising six urologists. This initial clinic is also using Cxbladder Monitor. Kaiser Permanente plans to progressively roll out Cxbladder Triage, alongside Cxbladder Monitor, across their network. Kaiser Permanente will use Pacific Edge's Patient In-Home Sample System for Cxbladder Triage, as is currently being done with Cxbladder Monitor, providing a simple and convenient way for both the patient and the physician to manage urine sample collection. CEO of Pacific Edge, David Darling, said: "We are delighted to continue the growth of our commercial partnership with Kaiser Permanente. Since reaching commercial agreement with Kaiser Permanente we have focused on working with them to provide their urologists with a great user experience. This requires successfully integrating Cxbladder into their internal electronic medical records systems to ensure that our products and services are easily accessible to their urologists and patients. While Covid-19 continues to impact the speed of the Cxbladder rollout across the Kaiser Permanente network, going forward we expect that their demand for Cxbladder will continue to increase as Covid-19 related restrictions ease and they expand the use of the use of two Cxbladder products." ENDS For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800 For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. ABOUT Cxbladder Triage www.cxbladder.com Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma. ABOUT Cxbladder Detect www.cxbladder.com Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy. ABOUT Cxbladder Monitor www.cxbladder.com Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer. ABOUT Cxbladder Resolve www.cxbladder.com Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings. Refer to www.cxbladder.com for more information. End CA:00374228 For:PEB Type:GENERAL Time:2021-06-21 09:33:38